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The European Institute for Innovation through Health Data (i~HD, www.i‐hd.eu) has been
formed as one of the key sustainable entities arising from the Electronic Health Records for Clin-
ical Research (IMI‐JU‐115189) and SemanticHealthNet (FP7‐288408) projects, in collaboration
with several other European projects and initiatives supported by the European Commission.
i~HD is a European not‐for‐profit body, registered in Belgium through Royal Assent. i~HD has
been established to tackle areas of challenge in the successful scaling up of innovations that crit-
ically rely on high‐quality and interoperable health data. It will specifically address obstacles and
opportunities to using health data by collating, developing, and promoting best practices in infor-
mation governance and in semantic interoperability. It will help to sustain and propagate the
results of health information and communication technology (ICT) research that enables better
use of health data, assessing and optimizing their novel value wherever possible. i~HD has been
formed after wide consultation and engagement of many stakeholders to develop methods, solu-
tions, and services that can help to maximize the value obtained by all stakeholders from health
data. It will support innovations in health maintenance, health care delivery, and knowledge dis-
covery while ensuring compliance with all legal prerequisites, especially regarding the insurance
of patient's privacy protection. It is bringing multiple stakeholder groups together so as to ensure
that future solutions serve their collective needs and can be readily adopted affordably and at
scale.1 | MOTIVATION: SCALING UP THE
ACCEPTABLE ACCESS, INTEGRATION, AND
USE OF HEALTH DATA
There are common needs spanning clinical research and health care, at
European, national, and local levels, for accessing, combining, and using
high‐quality health data on a large scale while complying with data and
patient privacy protection legislation (Figure 1).1.1 | Clinical research needs
Around half of clinical trials fail to meet their recruitment targets.1
Obstacles to conducting clinical trials today include high cost, lengthy
time frames, administrative barriers, and delays in study execution.2
These include assessing and optimizing the feasibility of clinical trial
protocols and identifying suitable patients for recruitment in clinical
trials. A third of (costly) clinical trial protocol amendments aree Creative Commons Attribution‐N
d and is not used for commercial
lished by Wiley Periodicals, Inc. o
wileyonlinelibraravoidable.3 Regulators, health technology assessors, and payers
require greater evidence of the effectiveness of innovative medicines
and their safety once licensed and will require even more fine‐grained
evidence as adaptive licensing extends across Europe including in real‐
world settings.4 Routinely collected data from electronic health
records (EHRs), sometimes known as real‐world data, therefore, now
needs to be better harnessed to gather such evidence: to enhance
and speed up drug development, increase efficiency, and generate
added value for clinical trial sponsors, health systems, and patients.51.2 | Health care needs
Health data are captured today at a variable quality and are not col-
lected or stored consistently, and the adoption of interoperability stan-
dards is far from ideal. At the level of the individual patient, guideline
and decision support systems, notification and alerting components,
and analytic tools need to process integrated health data drawn fromonCommercial License, which permits use, distribution and reproduction in any
purposes.
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FIGURE 1 i~HD has been formed in response to a convergence of clinical research and health care needs
*These projects include PARENT, TRANSFoRm, EMIF, SALUS, EXPAND, Trillium
Bridge, ASSESS CT, and VALUeHEALTH.
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public health bodies also need fine‐grained activity and outcome data to
inform service planning, commissioning, and prevention/wellness programs.
Electronic health records and personal health records need to be able to
share information and care pathways so as to empower patients tomanage
more of their own care and to play a stronger role in decision making.
Some of the major challenges faced across the research to health
care spectrum (ie, the learning health systems spectrum) relating to
enabling best learning use of health data are as follows: (1) information
governance, privacy protection, and ethics and (2) the quality and
interoperability (especially semantic interoperability) of health data. A
further challenge is the present day limited availability of evidence that
investments in health information and communication technology (ICT;
especially large‐scale investments such as national programs) actually
deliver significant benefits from more and more computable health
data. This relative lack of evidence (which may be in part because the
evidence from each ICT “intervention” is hard to isolate and be directly
attributable and in part because most programs invest little in evalua-
tion) hampers the construction of convincing business models and
plans to scale up the adoption of eHealth solutions and to sustain them.
The data processed in health care are very sensitive data, which
imply a high risk for a patient's privacy. Therefore, the success of innova-
tion in this field is highly dependent on the ability to gain and maintain
patient trust. A major prerequisite in this regard is that any electronicsystem is built on high data protection standards, which are fully compli-
ant with the respective legal framework. Therefore, information gover-
nance is a core part of the activities of European Institute for
Innovation through Health Data (i~HD), because it ensures the imple-
mentation of the legal requirements at all stages. In addition, it makes
the measures taken transparent for ethics committees and patients and
thus serves the goal of adequate communication with all stakeholders.2 | THE OBJECTIVES OF i~HD
The i~HD has been formed as one of the key sustainable entities arising
from the Electronic Health Records for Clinical Research (EHR4CR6) and
SemanticHealthNet7 projects, in collaborationwith several other European
projects and initiatives supported by the European Commission.*
The following objectives are reflected within the Articles of
Association that define i~HD.
Defining and supporting the adoption of best practices in informa-
tion governance, including complying with legislation and ethics, pri-
vacy protection, and codes of conduct, relating to the trustworthy
use of health data including capture, processing, and sharing.
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ing, curating, protecting, and exchanging health data in a trustworthy,
legally compliant, and transparent manner using best practices. This is
to enable complete and interoperable health records on individuals and
populations to deliver benefits to all stakeholders, supporting and guiding
the best use of standards and assets for semantic interoperability and pri-
vacy protection. These benefits will relate to the care given to individual
patients, to the configuration of health care and wellness services for
populations, and to the reuse of health data for knowledge discovery.
Providing and/or fostering capabilities to enable better quality health
data, and the legitimate sharing and uses of health data, including
semantic interoperability info‐structures and assets, exchange and
research platforms and tools, informatics standards and resources to
support standards adoption, de‐identified health data repositories,
and research data source catalogues and metadata.
Facilitating, deriving, and using intelligence from health data (scientific
and clinical intelligence, research, knowledge discovery, service improve-
ment, and business intelligence) through advancing the uses of a wide
range of potential data sources. These sources primarily are as follows:
electronic health and care records and personal health records, citizen
sourced and mobile health data, registries and claims databases, cohort
studies and biobanks, and clinical trial and electronic case report forms.
Performing and commissioning quality assessments, and conducting
quality audits of health data, ICT systems and applications, personnel
competence, and training and organizational processes relating to the
use of health data. Such audits may, for example, relate to the gover-
nance of the capture, usage, and communication (sharing) of health
data, or to the quality of health data at a given site such as a hospital.
Building synergy and consensus: acting as a focal point bringing stake-
holders together to share experiences, agree common priorities, and
approaches for maximizing the benefits of good quality and interopera-
ble health data and the trustworthy reuse of health data. i~HD is work-
ing toward convergence and cross‐fertilization between: health care
providers, patients and families, health ministries and insurers, EHR sys-
tem vendors and standards development organizations, pharma, and the
clinical research community, national, andmultinational decisionmakers.3 | MISSION AND SCOPE OF i~HD
i~HDhas been established in recognition of the need to sustain and prop-
agate the results of research projects, to tackle areas of challenge in the
successful scaling up of innovations drawing on health data. It is specifi-
cally addressing obstacles and opportunities in making greater use of
health data, such as collating and promoting best practices in information
governance and in semantic interoperability. Most importantly, i~HD
brings multiple stakeholder groups together so as to ensure that future
solutions serve their collective needs and add tangible value and can be
readily adopted affordably and at scale, in away that is socially acceptable.
The mission of i~HD is to enable, coordinate, and accelerate the
efficient development and deployment of interoperable and seamless
eHealth solutions and research strategies, toward achieving best prac-
tices and sustainable integrated person‐centered health care, to opti-
mize health and wellness in Europe, and beyond. It aims to guide andcatalyze the best, most efficient, and trustworthy uses of health data
and interoperability, for optimizing health and knowledge discovery.
Examples of knowledge discovery in this context include the use
of health data to derive local knowledge (for example, to determine
quality of care or to monitor the adoption of a care pathway) or
generalizable knowledge that supports optimizing care effectiveness,
safety and equity, developing or evaluating new health care services
and products (such as medicines and devices), epidemiological and
observational research, and the conduct of prospective research such
as using health data to identify patients to participate in research
studies. All of these are essential ingredients of a learning health system.
There are other organizations, active at a European level, making
contributions in this general direction. The eHealth Network8 brings
together health ministries and other high‐level eHealth decision
makers across Europe to agree on common areas of strategy and stan-
dardization in the field of eHealth. The European Institute for Health
Records (EuroRec9) promotes the high‐quality use of EHR systems
and provides quality labeling and certification services for this. Inte-
grating the Healthcare Enterprise10 defines interoperability profiles
for user‐driven use cases and provides testing and certification ser-
vices for this. CEN TC/25111 is increasingly acting as a European
forum for many other standards development organizations at a Euro-
pean level. The European Clinical Research Infrastructure Network12
assures the quality of clinical research organizations. Many health care
professions and specialties have European associations that agree on
good practices and develop guidelines and audit data sets to promote
best practices for their specific domains. There are specialist associa-
tions catering for particular stakeholder groups such as the European
Federation of Pharmaceutical Industries and Associations13 and
umbrella organizations for patient associations. However, none are
working across the rich range of domains and stakeholders who need
to be involved in cocreating the solutions to complex problems (such
as advanced technological platforms) centering on the use of health
data. Although i~HD is constituted as a European entity, its mission,
the challenges that it is addressing, and the approaches it is developing
and promoting all have global applicability, and it is therefore seeking
to collaborate with other organizations internationally to enable these
issues to be tackled coherently on a global level.
i~HD has been established, after an extensive consultation and
engagement process involving many stakeholders, to fill a recognized
gap: to develop and maintain methods, solutions, and services that can
help to maximize the value generated for all stakeholders from optimizing
the use of health data and to support innovations in health maintenance
and health care delivery and in knowledge discovery. It wishes to work
with the above groups, and others not mentioned here, to complement—
not duplicate—their activities and to address issues that remain outstand-
ing and are of importance to be resolved. While having a clear initial work
plan focused on enabling the trustworthy reuse of health data for research
and promoting better semantic interoperability of health data, i~HD is
seeking to respond in an agile and coherent way to new needs and oppor-
tunities that can enable its stakeholdermembers, health systems, and soci-
ety as a whole to maximize the value derived from health data.
i~HD is a European not‐for‐profit body, registered in Belgium
through Royal Assent. It is governed by its member stakeholders, pub-
lic and private, through elected board and officers. Each of the main
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which they will elect or re‐elect annually through a general assembly.
The board will determine the strategy of the institute, appoint its exec-
utive officers, and approve its annual budget. The institute is being
financed by a mixture of membership subscriptions, fees from provid-
ing services such as certification and accreditation, specific project
grants, and other income from education, training, and expert advisory
roles.4 | PROMOTING AND ENABLING THE
TRUSTWORTHY REUSE OF HEALTH DATA
FOR RESEARCH
European projects, future call topics for Horizon 2020 proposals,
national research infrastructure programs, and real‐world studies to
assess the effectiveness, safety, and cost‐effectiveness of innovative
medicines in routine medical practice, including large observational
studies funded by pharmaceutical industry, all point to the growing
interest among many stakeholders to collaborate and tackle on a large
scale access to high‐quality, integrated, and appropriately protected
health data to conduct research.
Concerns about the protection of privacy when health data are
integrated or shared, even for direct patient care as well as for aggre-
gated data purposes, limit the extent to which even the data we have
today can be combined, aggregated, and analyzed appropriately. How-
ever, a number of European initiatives are making progress in address-
ing these issues and are generating solutions for the reuse of health
data for research that are ready to be adopted, at scale.
Electronic Health Records for Clinical Research has developed an
innovative technological platform that can connect securely to the
data within multiple hospital EHR systems and clinical data ware-
houses across Europe, to enable a trial sponsor to predict the number
of eligible patients for a candidate clinical trial protocol, to assess its
feasibility, and to locate the most relevant hospital sites, all contribut-
ing to enhance and improve the efficiency of existing clinical research
processes.5,14,15 Applications for internal use are offered to connected
hospitals to assist them to efficiently identify and contact the patients
who may be eligible for particular clinical trials. Contrary to other initia-
tives, EHR4CR designed a solution that is compliant to European
Union legislation and respects the position of hospital and patients.
One of the key aspects is that patient‐level data never leave the
connected hospitals. The platform and services are now beinglaunched by the first commercial service provider, Custodix,16 ready
for Europe‐wide deployment and use.17
The European Medical Information Framework (EMIF) is creating
an environment that allows the efficient research reuse of existing
health data repositories such as cohort studies and bio‐banks, as well
as EHRs. The EMIF Platform will allow authorized access to multiple,
diverse data sources, at present spanning primary and secondary care
data from nearly 48 million subjects in 7 European countries. The EMIF
Platform will integrate data cohorts and conduct data source profiling,
allowing researchers to browse metadata, providing them with a single
point of access for searching aggregated data across different sources
and countries, and enabling them to answer specific research ques-
tions on identifying and validating novel biomarkers.
The TRANSFoRm project has developed a research data architec-
ture to implement the learning health system in general practice, using
outcomes data to develop new evidence that can be delivered back as
computable rules, to improve clinical decision making.18 TRANSFoRm
has specified a strong separation between zones for clinical use and
research use, and the provision of pseudoidentification and linkage
services managed within a trusted “middle” zone.19
For all of these projects, it has been important to establish infor-
mation governance, privacy protection, and information security mea-
sures that enable their large‐scale reuse of health data in full
compliance with the applicable legislation, and in a way that is socially
acceptable. Each project, and others in this field, has developed
methods and instruments that contribute to overall trust in the
research reuse environment, but there is a need for a consolidation
of these approaches and for a single source to publish and maintain
harmonized best practices. i~HD is specifically supporting the develop-
ment, harmonization, promotion, and sustainability of these best prac-
tices in the reuse of health data for research. Its experts have started
working on an overarching set of high‐level principles and standard
operating rules that bring together these project results, combining
themwith other relevant instruments developed within the informatics
and bioinformatics communities. An important governance starting
point is the recently published Innovative Medicines Initiative20 Code
of Practice on secondary use of medical data in European scientific
research projects (Figure 2).21
With an initial focus on EHR4CR, which is to go live in early 2016,
i~HD is ensuring that all parties involved in the EHR4CR ecosystem
operate in full compliance with all applicable requirements and policies,
by certifying the ICT systems, overseeing their operation, auditing the
information flows, and establishing good practices in informationFIGURE 2 The services provided by i~HD to
facilitate the trustworthy reuse of health data
for research. ICT, information and communi-
cation technology
FIGURE 3 The activities needed to scale up
semantic interoperability and the adoption of
standards (EC = European Commission, SDO =
Standards Development Organization)
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i~HD has no legal or assigned mandate to apply such governance, to
require compliance with audit, or to apply sanctions, but in view of
the importance of this issue, the participating pharma companies have
all agreed to abide by such measures and agreed that they may be
included as stipulations within contracts that they are signing for use
of the platform. Participating hospitals have likewise agreed to comply
with these measures. It is developing and promoting best practices for
the wider use of EHRs for research, including engagement with patient
associations, privacy protection agencies, and regulatory authorities to
ensure the solution is well accepted by all of them and generates ben-
efits. The activities i~HD will embark upon during 2016 to promote
this trustworthy research ecosystem are listed in Box 1.‡These EXPAND results are not yet published.5 | FOSTERING AND COORDINATING AN
ECOSYSTEM FAVORING STANDARDS
ADOPTION AND INTEROPERABLE
SOLUTIONS
Health data are captured today at a variable quality and are not col-
lected or stored consistently in the EHR systems of different vendors,
and standards adoption is far from ideal. There are many organizations,
initiatives, and research projects tackling different aspects of this inter-
operability challenge. However, research results have not proved easy
to sustain and are therefore frequently reinvented by successor projects
rather than enriched. Initiatives are often driven by individual stake-
holder groups in isolation, such as health informatics standards bodies
developing isolated standards. Health professional bodies develop
guidelines in a narrative formwithout specifying how conforming health
records should be structured. Performance targets are set for health care
providers that require the specific collection of reporting data that is not
related to the data that needs to be collected to support patient care.
Semantic interoperability, which is about ensuring that the mean-
ing of clinical data can be correctly interpreted when it is shared
between EHR system from different applications within and cross‐bor-
der, is a priority area for i~HD. Its members are already working with
many European projects and key stakeholders to define the top prior-
ities and the good practices for developing and implementing semantic
interoperability standards, for example, to enable safe and efficient
continuity of care between professionals looking after a patient with
a long‐term condition, who may be employed in different organizations
and working on different sites. Examples of projects whose resultshave already contributed to i~HD's support for semantic interoperabil-
ity include SemanticHealthNet, which has defined good practices in
multistakeholder engagement in the definition of semantic interopera-
bility needs and assets,22,23 and EXPAND, which has developed a set
of quality label descriptors for interoperability assets (Figure 3).‡
i~HD will promote the importance of interoperability, in particular
establishing strong links with standards development organizations and
industry to promote the adoption of standards. It will help to bring
together the patients and clinicianswho create and usemost health infor-
mation with other critical stakeholders such as the health ICT industry,
standards developers, clinical research communities, and health care
funders, to cocreate the most relevant future standards and champion
their adoption. This work will take into account of and align as closely
as possible with, the eHealth European Interoperability Framework24
and with the recently published Interoperability Roadmap by the US
Health andHuman ServicesOffice of theNational Coordinator for Health
Information Technology.25 The activities that i~HDwill embark upon dur-
ing 2016 to promote better semantic interoperability are listed in Box 2.
i~HD is keen to promote the engagement and empowerment of
patients in health decision making and in illness self‐management,
and for all citizens to have access to information about their health sta-
tus so as to make informed choices that promote wellness and prevent
disease. Semantic interoperability, including the ability to communicate
health information effectively and meaningfully to patients, is critical
to enabling well‐informed coproduction of health and decision making.6 | DEMONSTRATING VALUE FROM THE
USE OF HEALTH DATA
It is expensive and complex to implement interoperable EHR systems,
to develop and disseminate good practices in the systematic and con-
sistent documentation of health data, and to grow the systems and cul-
ture of making good use of shareable computable health data. Most
health ICT investments are slow to deliver benefits, and it is especially
difficult to demonstrate tangible benefits from ICT solutions when
richer socio‐technical change is needed to achieve them.
There are many perverse incentives not to adopt standards, many
of which are locked into antiquated models of health care reimburse-
ment, antiquated models of procurement, and antiquated supplier rela-
tionships with customers. Standards bodies publish standards, as
BOX 1. Planned activities for 2016 to promote a
trustworthy ecosystem for reusing health data for
research.
Best practices in information governance
• maintain and promote codes of best practice in
information governance, privacy protection, and
ethics for the uses for health data, especially for
research and also for cross‐border health care
and public health;
• work with key decision makers and influencers to
mutually agree good practices that balance
societal benefit and personal privacy.
Certification of health research platforms, services,
and tools
• develop and deliver, primarily in partnership with
EuroRec, quality labeling criteria, a test plan and
certification process for platforms, services, and
tools supporting the reuse of health data for
research, with an initial focus on certifying
conformance to the EHR4CR specifications;
• maintain and publish the specifications of services
and interfaces for clinical research platforms and
tools, to which conformance can be tested.
Accreditation of clinical research staff
• develop and promote, primarily in partnership
with UKCHIP† and ECRIN, a code of practice
for staff using health data for research, and
provide an accreditation process to recognize
the necessary skills in clinical research staff.
Governance oversight of clinical research platform
service providers
• provide an independent oversight body governing
the ecosystem in which health data are used for
research, through institute‐certified ICT
products, platforms, and services.
Network of excellence for research through health
data
• foster and coordinate a multistakeholder
community involving those who collect,
integrate, manage, and analyze health data for
research, so as to cocreate and promote good
practices, identify challenges needing new
research and innovations, grow the evidence for
measures that scale up and speed up the
adoption of innovations, and deliver education
and provide accreditation.
BOX 2. Planned activities for 2016 to promote better
semantic interoperability between EHR systems.
Fostering the codesign of semantic interoperability
assets by clinicians, patients, and research
• supports the development of good‐quality
semantic interoperability assets that are well
suited to addressing high priority needs for
sharing health information;
• designs quality processes for clinical information
models and terminology value sets.
Quality labeled public directory of interoperability assets
• publish an online register to act as a central reference
point to discover which interoperability assets may
be used, together, to tackle a particular use case;
• develop and maintain a set of services that can
support research and development projects and
other initiatives to mature their novel
interoperability assets to the level at which they
can be published and reused by others;
• facilitate convergence and reuse of existing
assets, in preference to reinvention.
Semantic harmonization services
• maintain a list of data items and mappings across
terminology systems, to support the harmonization
of data and queries in support of clinical research,
especially clinical trial feasibility and patient
recruitment, and patient summaries to support
continuity of care across Europe;
• maintain the service specification of a central
semantic broker to support the construction of
local mappings between the data dictionary of a
hospital or general practice EHR system and a
centralized representation.
Semantic interoperability evidence base
• collate and synthesize worldwide experience and
learning of success strategies for scaling up
semantic interoperability, of demonstrating value
and deriving benefits from sharing and analyzing
semantically interoperable health information.
SemanticHEALTH Alliance
• hosts and coordinates a network of stakeholder
communities that collaborate to enable the
development and successful adoption of relevant
and usable semantic interoperability standards.
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oversee and promote the assessment of value of standards as a whole,
and to highlight targeted use cases where standards can play an impor-
tant enabling role.†The UK Council for Health Informatics Professionals. http://www.ukchip.orgMany research projects and pilots that do undertake innovative
interoperability initiatives lack the budget and time to undertake good‐
quality evaluations, limiting the global body of available evidence of value.
There is a need to better harness the best available evidence so as to
guide and optimize future strategic investments, to promote and direct
standards adoption, and thereby to accelerate the delivery of benefits,
particularly those relevant in the context of learning health systems.
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success strategies, and warnings from across large‐scale pilots and
large‐scale deployments of eHealth and of the reuse of health data
for research. It will collect and synthesize evidence frameworks
(existing systematic reviews, best practice guidelines, well‐regarded
case study reports, and data collection templates) and develop stan-
dards adoption guidelines, illustrated with successful case studies.
i~HD will also actively promote the assessment of evidence of benefits
compared with current standards, as these emerge to help stimulate
the market for good‐quality health ICT products, for their successful
use, and of the value to all of collecting and using good‐quality health
data.7 | CONCLUSION
More and more health data are being collected across care organiza-
tions, and increasingly by patients directly, providing formidable new
opportunities for learning health system environments. Nonetheless,
there is limited capability for these data to be brought together and
interpreted collectively to enable better patient care, organizational
learning, or research. The most important obstacles to making better
use of health data are well known and include the following: the weak
incentives for busy clinicians to capture high‐quality health data; a
marketplace for health ICT products that does not favor well the adop-
tion of interoperability standards; a current generation of standards
that are still poorly matched to the semantic interoperability needs of
clinicians, patients, public health, and research; the challenges of legit-
imately reusing health data for research while protecting patient pri-
vacy; the tendency for projects and initiatives to reinvent approaches
to the representation and protection of health data; and the overall
limited evidence base to confirm that all of this effort to improve the
quantity and quality and interoperability of health data will actually
deliver significant benefits.
i~HD (www.i‐hd‐eu) has been formed so as to provide a point of
consolidation of best practices in emerging solutions to these issues,
and to help to develop new practices and strategies where there are
gaps. It will work with many existing organizations in eHealth and clin-
ical research, initially in Europe, but always to focus on the delivery of
concrete solutions and the support of a multistakeholder ecosystem
favoring better learning from health data.
i~HD was formally launched through an inaugural conference in
Paris, on March 10, 2016. This was attended by over 200 clinicians,
health care providers, and researchers from across Europe, as well as
representatives of the pharma industry, patient associations, health
professional associations, the health ICT industry, and standards bod-
ies. The event showcased the issues and approaches discussed in this
paper and presented the specific activities that i~HD intends to pur-
sue, as indicated in Boxes 1 and 2 above.REFERENCES
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